Reproductive · Obstetrics and Gynecology
The facts most likely to be tested
All women of reproductive age should initiate folic acid supplementation (0.4–0.8 mg daily) at least one month prior to conception to reduce the risk of neural tube defects.
Patients with a history of a prior pregnancy affected by a neural tube defect or those on antiepileptic drugs require a high-dose folic acid regimen of 4 mg daily.
Preconception screening for rubella and varicella immunity is mandatory, with live-attenuated vaccines administered at least one month before conception if the patient is non-immune.
Patients with pre-gestational diabetes must achieve optimal glycemic control (HbA1c < 6.5%) prior to conception to minimize the risk of congenital malformations and spontaneous abortion.
Teratogenic medications such as ACE inhibitors, ARBs, isotretinoin, and valproate must be discontinued or switched to safer alternatives like methyldopa, labetalol, or levetiracetam before pregnancy.
Universal screening for cystic fibrosis, spinal muscular atrophy, and hemoglobinopathies should be offered based on ethnicity and family history.
Patients with hypothyroidism require an increase in levothyroxine dosage as soon as pregnancy is confirmed to meet the increased metabolic demands of the fetal thyroid.
Vignette unlocked
A 28-year-old woman presents for a preconception visit. She has a history of epilepsy currently managed with valproate. She is sexually active and not using contraception. Her physical exam is unremarkable, and her BMI is 24 kg/m². She expresses a desire to conceive within the next few months.
What is the most appropriate next step in the management of this patient?
Switch valproate to a safer antiepileptic drug and initiate 4 mg of folic acid daily.
This tests the knowledge of teratogenic medications and high-dose folic acid requirements; valproate is highly teratogenic (neural tube defects), and patients on antiepileptics require higher folic acid doses.
Full handout
High yield triage
Etiology / Epidemiology
All women of reproductive age require folic acid supplementation to prevent neural tube defects. Screen for chronic conditions (DM, HTN) and teratogenic medications prior to conception.
Clinical Manifestations
Assess for pre-gestational comorbidities. HbA1c < 6.5% is the target for diabetic patients to minimize congenital malformations.
Diagnosis
Perform serologic screening for rubella, varicella, and HIV. Confirm rubella immunity via IgG titers; vaccinate if non-immune.
Treatment
Initiate 0.4–0.8 mg folic acid daily. Teratogenic drugs like ACE inhibitors and isotretinoin must be discontinued.
Prognosis
Optimizing maternal health reduces perinatal mortality and congenital anomalies. Preconception care is the most effective intervention for fetal outcomes.
Full handout
Epidemiology & Etiology
Preconception care targets the modification of behavioral, biomedical, and social risks. Advanced maternal age (>35) increases risk for aneuploidy. Patients with pre-existing diabetes or epilepsy require medication adjustment to avoid teratogenicity.
Pertinent Anatomy
The neural tube closes by day 28 post-conception, necessitating early intervention. Uterine anatomy, such as bicornuate uterus, should be evaluated if there is a history of recurrent pregnancy loss.
Pathophysiology
Hyperglycemia during organogenesis leads to caudal regression syndrome and cardiac defects. Chronic hypertension causes placental insufficiency and intrauterine growth restriction. Inadequate folate intake disrupts DNA synthesis, leading to anencephaly or spina bifida.
Clinical Manifestations
Review medication lists for teratogenic agents including valproic acid, lithium, and warfarin. Screen for TORCH infections if symptomatic. Red flags include uncontrolled seizures or hypertensive crisis requiring immediate stabilization.
Diagnosis
Obtain baseline TSH to rule out subclinical hypothyroidism. Perform hemoglobin electrophoresis if the patient is at risk for sickle cell disease or thalassemia. Rubella IgG status is mandatory; if negative, administer the MMR vaccine at least 1 month before conception.
Treatment
Prescribe folic acid 0.4 mg daily for low-risk patients; increase to 4 mg for those with a history of prior neural tube defects. Switch ACE inhibitors to methyldopa or labetalol for hypertension. Contraindicated medications must be replaced with safer alternatives at least 3 months prior to conception.
Prognosis
Strict glycemic control reduces the risk of macrosomia and neonatal hypoglycemia. Early identification of Rh-negative status allows for timely Rho(D) immune globulin administration during pregnancy to prevent isoimmunization.
Differential Diagnosis
Uncontrolled Diabetes: high risk of caudal regression
Hypothyroidism: associated with infertility and miscarriage
Epilepsy: risk of teratogenicity from anticonvulsants
Hypertension: risk of preeclampsia and placental abruption
Genetic Carrier Status: risk of autosomal recessive disorders